Literature DB >> 31823251

CNS Neurotoxicity of Antiretrovirals.

Tyler Lanman1, Scott Letendre2, Qing Ma3, Anne Bang4, Ronald Ellis5.   

Abstract

The development of novel antiretroviral treatments has led to a significant turning point in the fight against HIV. Although therapy leads to virologic suppression and prolonged life expectancies, HIV-associated neurocognitive disorder (HAND) remains prevalent. While various hypotheses have been proposed to explain this phenomenon, a growing body of literature explores the neurotoxic effects of antiretroviral therapy. Research to date brings into question the potential role of such medications in neurocognitive and neuropsychiatric impairment seen in HIV-positive patients. This review highlights recent findings and controversies in cellular, molecular, and clinical neurotoxicity of antiretrovirals. It explores the pathogenesis of such toxicity and relates it to clinical manifestations in each medication class. The concept of accelerated aging in persons living with HIV (PLWH) as well as potential treatments for HAND are also discussed. Ultimately, this article hopes to educate clinicians and basic scientists about the neurotoxic effects of antiretrovirals and spur future scientific investigation into this important topic. Graphical Abstract.

Entities:  

Keywords:  Antiretroviral; Antiretroviral therapy; HAND; HIV; Neurocognitive; Neurotoxicity

Mesh:

Substances:

Year:  2019        PMID: 31823251      PMCID: PMC7282963          DOI: 10.1007/s11481-019-09886-7

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  139 in total

1.  Updated research nosology for HIV-associated neurocognitive disorders.

Authors:  A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

Review 2.  Efavirenz and the CNS: what we already know and questions that need to be answered.

Authors:  Nadezda Apostolova; Haryes A Funes; Ana Blas-Garcia; Maria J Galindo; Angeles Alvarez; Juan V Esplugues
Journal:  J Antimicrob Chemother       Date:  2015-07-22       Impact factor: 5.790

3.  Host-pathogen interactions in the development of metabolic disturbances and atherosclerosis in HIV infection: the role of CCL2 genetic variants.

Authors:  Carlos Alonso-Villaverde; Gerard Aragonès; Raúl Beltrán-Debón; Laura Fernández-Sender; Anna Rull; Fernando Rodríguez-Sanabria; Judit Marsillach; Pedro Pardo-Reche; Jordi Camps; Jorge Joven
Journal:  Cytokine       Date:  2010-06-22       Impact factor: 3.861

4.  Molecular insights into NRTI inhibition and mitochondrial toxicity revealed from a structural model of the human mitochondrial DNA polymerase.

Authors:  Rachelle J Bienstock; Willliam C Copeland
Journal:  Mitochondrion       Date:  2004-07       Impact factor: 4.160

Review 5.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

6.  A cross-sectional study to evaluate the association of hyperbilirubinaemia on markers of cardiovascular disease, neurocognitive function, bone mineral density and renal markers in HIV-1 infected subjects on protease inhibitors.

Authors:  T J Barber; G Moyle; A Hill; G Jagjit Singh; A Scourfield; H M Yapa; L Waters; D Asboe; M Boffito; M Nelson
Journal:  HIV Clin Trials       Date:  2016-05

7.  Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992.

Authors:  H Bacellar; A Muñoz; E N Miller; B A Cohen; D Besley; O A Selnes; J T Becker; J C McArthur
Journal:  Neurology       Date:  1994-10       Impact factor: 9.910

Review 8.  Neuropsychiatric side effects of efavirenz therapy.

Authors:  Gabriele Arendt; Dominique de Nocker; Hans-Juergen von Giesen; Thorsten Nolting
Journal:  Expert Opin Drug Saf       Date:  2007-03       Impact factor: 4.250

9.  Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients.

Authors:  Anchalee Avihingsanon; Stephen J Kerr; Baralee Punyawudho; Jasper van der Lugt; Meena Gorowara; Jintanat Ananworanich; Joep M A Lange; David A Cooper; Praphan Phanuphak; David M Burger; Kiat Ruxrungtham
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-02       Impact factor: 2.205

10.  Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.

Authors:  Alejandro Arenas-Pinto; Wolfgang Stöhr; Hans Rolf Jäger; Lewis Haddow; Amanda Clarke; Margaret Johnson; Fabian Chen; Alan Winston; Claudia Godi; Steffi Thust; Rita Trombin; Janet Cairns; Bhavana S Solanky; Xavier Golay; Nicholas I Paton
Journal:  Clin Infect Dis       Date:  2016-05-03       Impact factor: 9.079

View more
  13 in total

Review 1.  The potential role of HIV-1 latency in promoting neuroinflammation and HIV-1-associated neurocognitive disorder.

Authors:  Sheetal Sreeram; Fengchun Ye; Yoelvis Garcia-Mesa; Kien Nguyen; Ahmed El Sayed; Konstantin Leskov; Jonathan Karn
Journal:  Trends Immunol       Date:  2022-07-12       Impact factor: 19.709

Review 2.  Retroviral Elements in Pathophysiology and as Therapeutic Targets for Amyotrophic Lateral Sclerosis.

Authors:  Wenxue Li; Darshan Pandya; Nicholas Pasternack; Marta Garcia-Montojo; Lisa Henderson; Christine A Kozak; Avindra Nath
Journal:  Neurotherapeutics       Date:  2022-04-12       Impact factor: 6.088

Review 3.  Lessons for Understanding Central Nervous System HIV Reservoirs from the Last Gift Program.

Authors:  Patricia K Riggs; Antoine Chaillon; Guochun Jiang; Scott L Letendre; Yuyang Tang; Jeff Taylor; Andrew Kaytes; Davey M Smith; Karine Dubé; Sara Gianella
Journal:  Curr HIV/AIDS Rep       Date:  2022-10-19       Impact factor: 5.495

Review 4.  Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants.

Authors:  Shih-Ping Lin; Andrea Calcagno; Scott L Letendre; Qing Ma
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 5.  Treating viruses in the brain: Perspectives from NeuroAIDS.

Authors:  Melanie R Nicol; MaryPeace McRae
Journal:  Neurosci Lett       Date:  2021-01-30       Impact factor: 3.046

Review 6.  Crossroads of Drug Abuse and HIV Infection: Neurotoxicity and CNS Reservoir.

Authors:  Shilpa Sonti; Kratika Tyagi; Amit Pande; Rene Daniel; Adhikarimayum Lakhikumar Sharma; Mudit Tyagi
Journal:  Vaccines (Basel)       Date:  2022-01-27

7.  Efavirenz-Induced Delayed Onset Cerebellar Ataxia and Encephalopathy.

Authors:  Grk Sarma; Delon Dsouza; Savitha Sebastian; Priyanka Prakash
Journal:  Ann Indian Acad Neurol       Date:  2021-06-03       Impact factor: 1.383

Review 8.  Toxic Metals and Non-Communicable Diseases in HIV Population: A Systematic Review.

Authors:  Opeyemi M Folorunso; Chiara Frazzoli; Ifeyinwa Chijioke-Nwauche; Beatrice Bocca; Orish E Orisakwe
Journal:  Medicina (Kaunas)       Date:  2021-05-13       Impact factor: 2.430

9.  Higher Comorbidity Burden Predicts Worsening Neurocognitive Trajectories in People with Human Immunodeficiency Virus.

Authors:  Ronald J Ellis; Emily Paolillo; Rowan Saloner; Robert K Heaton
Journal:  Clin Infect Dis       Date:  2022-04-28       Impact factor: 20.999

Review 10.  Role of Inflammasomes in HIV-1 and Drug Abuse Mediated Neuroinflammaging.

Authors:  Susmita Sil; Fang Niu; Ernest T Chivero; Seema Singh; Palsamy Periyasamy; Shilpa Buch
Journal:  Cells       Date:  2020-08-08       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.